

DAFTAR PUSTAKA

1. WHO. Diarrhoeal disease. [cited 2023 Jul 27]. Available from: <https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease>
2. World Health Organization. Buku saku pelayanan kesehatan anak di rumah sakit. In: Tim adaptasi Indonesia, editor. Buku Saku Pelayanan Kesehatan Anak di Rumah Sakit. WHO; 2009:157–61.
3. Sudaryat S. Kapita Selekta Gastroenterologi. Sagung Seto;2007:3–5.
4. Kemenkes RI. Hasil riset kesehatan dasar tahun 2018. Kementerian Kesehatan RI. 2018;53:1689–99.
5. Lam YA, Warouw SM, Wahani AMI, Manoppo JIC, Salendu PM. Correlation between gut pathogens and fecal calprotectin levels in young children with acute diarrhea. Paediatr Indones. 2014;54:193–7.
6. Chen C chang, Huang J long, Chang C jen, Kong M shan. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. J Pediatr Gastroenterol Nutr. 2012;55:541–7.
7. Savitri TR, Hidajat S, Alam A. Pengaruh lactobacillus reuteri DSM 17938 terhadap kadar calprotectin feses sebagai penanda inflamasi intestinal pada bayi kurang bulan. Sari Pediatr. 2018;20:171–7.
8. Jurnal YD. Pengaruh pemberian dadih terhadap keseimbangan mikroflora usus dan tinggi vili ileum. Sari Pediatr. 2020;21:207-12.
9. Samsudin DD, Firmansyah A, Hidayati EL, Yuniar I. Effects of probiotic on gut microbiota i children with acute diarrhea : pilot study. Paediatr Indones. 2020;60:83–90.
10. McFarland L V. Efficacy of single-strain probiotics versus multi-strain mixtures: systematic review of strain and disease specificity. Dig Dis Sci. 2021;66:694–704.
11. Tremblay A, Xu X, Colee J, Tompkins TA. Efficacy of a multi-strain probiotic formulation in pediatric populations: a comprehensive review of clinical studies. Nutrients. 2021;13:1–19.
12. Soepardi J, Soenarto S, Agtini M. Buletin data dan kesehatan: situasi diare di indonesia. Kemenkes RI. 2011;2.
13. Bouzari S, Jafari A, Aslani MM. Escherichia coli: A brief review of diarrheagenic pathotypes and their role in diarrheal diseases in Iran. Iran J Microbiol. 2012;4:102–17.
14. Fitriyana F, Jurnal YD, Yerizel E. Perbedaan kadar alpha 1 antitrypsin feses berdasarkan tingkat keparahan diare akut pada anak. Sari Pediatr. 2018;19:267–72.
15. Antarini N. Sinbiotik antara prebiotik dan probiotik. Ilmu Gizi. 2011;2:148–55.

16. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*. 2014;11:506–14.
17. Holzapfel WH, Haberer P, Geisen R, Schillinger U. Taxonomy and important features of probiotic microorganisms in food and nutrition. 2018;73:365S-73S.
18. Pandey KR, Naik SR, Vakil B V. Probiotics, prebiotics and synbiotics- a review. *Journal of Food Science and Technology*. 2015;52:7577–87.
19. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. *PLoS One*. 2012:1–11.
20. Oo O, Ri A, Ft O. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women (Review). *Cochrane Collab*. 2009:1–14.
21. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. *Cochrane Database Syst Rev*. 2015;2015:1–19.
22. Doron S, Snyderman DR. Risk and safety of probiotics. *Clin Infect Dis*. 2015;60:S129-34.
23. Thomsen M. Probiotics-enhancing health with beneficial bacteria. *Altern Complement Ther*. 2006;14–21.
24. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. *Pediatrics*. 2005;115:5–9.
25. Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. *Adv Exp Med Biol*. 2008;606:423–54.
26. Sanz Y, Nadal I, Sanchez E. Probiotics as drugs against human gastrointestinal pathogens. *Front Anti-Infective Drug Discov*. 2012;107–23.
27. Gupta V, Bamezai RNK. Human pyruvate kinase M2: a multifunctional protein. *Protein Sci*. 2010;19:2031–44.
28. Khanna V, Alam S, Malik A, Malik A. Efficacy of tyndalized lactobacillus acidophilus in acute diarrhea. *Indian J Pediatr*. 2005;72:935–8.
29. Montoudis A, Delvin E, Menard D, Beaulieu JF, Jean D, Tremblay E, et al. Intestinal-fatty acid binding protein and lipid transport in human intestinal epithelial cells. *Biochem Biophys Res Commun*. 2006;339:248–54.
30. Szajewska H, Setty M, Mrukowicz J, Guandalini S. Probiotics in gastrointestinal diseases in children. *J Pediatr Gastroenterol Nutr*. 2006;42:454–75.
31. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzæg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. *J Clin Pathol - Mol Pathol*. 1997;50:113–23.
32. Pashapour N, Iou SG. Evaluation of yogurt effect on acute diarrhea in 6-24-month-

old hospitalized infants. *Turk J Pediatr.* 2006;48:115–8.

33. Bernaola Aponte G, Bada Mancilla CA, Carreazo NY, Rojas Galarza RA. Probiotics for treating persistent diarrhoea in children. *Cochrane Database Syst Rev.* 2013;1–7.
34. Collinson S, Deans A, Padua-Zamora A, Gregorio G V., Li C, Dans LF, et al. Probiotics for treating acute infectious diarrhoea. *Cochrane Database Syst Rev.* 2020;2020:1–186.
35. Herrera OR, Christensen ML, Helms RA. Calprotectin: clinical applications in pediatrics. *J Pediatr Pharmacol Ther.* 2016;21:308–21.
36. Vogel HJ. Lactoferrin, a bird's eye view. *Biochem Cell Biol.* 2012;90:233–44.
37. Burge PS, Johnson WS, Hayward AR. Neutrophil pyruvate kinase deficiency with recurrent staphylococcal infections: first reported case. *Br Med J.* 1976;1:742–5.
38. Pelsers MMAL, Hermens WT, Glatz JFC. Fatty acid-binding proteins as plasma markers of tissue injury. *Clin Chim Acta.* 2005;352:15–35.
39. Korndörfer IP, Brueckner F, Skerra A. The crystal structure of the human (S100A8/S100A9)₂ heterotetramer, calprotectin, illustrates how conformational changes of interacting α -helices can determine specific association of two EF-hand proteins. *J Mol Biol.* 2007;370:887–98.
40. Fagerhol MK. Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein? *Mol Pathol.* 2007;49:M74-9.
41. Dale H fagerhol; Quantitation of a leukocyte protein (L1) in urine. 1983;615–6.
42. Odink K, Cerletti N, Brüggem J, Clerc RG, Tarcsay L, Zwadlo G, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. *Nature.* 1987;330:80–2.
43. Wilson GB, Jahn TL, Fonseca JR. Demonstration of serum protein differences in cystic fibrosis by isoelectric focusing in thin-layer polyacrylamide gels. *Clin Chim Acta.* 1973;49:79–91.
44. Wilkinson MM, Busuttill A, Hayward C, Brock DJ, Dorin JR, Van Heyningen V. Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues. *J Cell Sci.* 1988;91:221–30.
45. Freemont P, Hogg N, Edgeworth J. Sequence identity. *Nature.* 1989;339:516.
46. Meijer B, Gearry RB, Day AS. The role of S100A12 as a systemic marker of inflammation. *Int J Inflam.* 2012;2012:1–6.
47. McMahan CW, Chhabra R. The role of fecal calprotectin in investigating digestive disorders. *J Lab Precis Med.* 2018;3:1–6.
48. Vaos G, Kostakis I, N Z, Chatzemichael A. The role of fecal calprotectin in pediatric disease. *Korean J Pediatr.* 2019;2019:1–8.

49. Guandalini S. Probiotics for children with diarrhea: an update. *J Clin Gastroenterol*. 2008;42:53–7.
50. Dale I. Plasma levels of the calcium-binding LI leukocyte protein: Standardization of blood collection and evaluation of reference intervals in healthy controls. *Scand J Clin Lab Invest*. 1990;50:837–41.
51. Dunlop O, Bruun JN, Myrvang B, Fagerhol MK. Calprotectin in cerebrospinal fluid of the HIV infected: a diagnostic marker of opportunistic central nervous system infection? *Scand J Infect Dis*. 1991;23:687–9.
52. Cuida M, Brun JG, Tynning T, Jonsson R. Calprotectin levels in oral fluids: the importance of collection site. *Eur J Oral Sci*. 1995;103:8–10.
53. Dale I, Fagerhol MK, Frigård M. Quantitation of a highly immunogenic leukocyte antigen (L1) by radioimmunoassay: methodological evaluation. *J Immunol Methods*. 1983;65:245–55.
54. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. *J Pediatr Gastroenterol Nutr*. 2002;34:323–5.
55. Fagerberg U, Loof L, Merzoug R, Hansson L, Yinkel. Fecal calprotectin levels in healthy children studied with an improved assay. *J Pediatr Gastroenterol Nutr*. 2003;37:468–72.
56. Hestvik E, Tumwine JK, Tylleskar T, Grahnquist L, Ndeezi G, Kaddu-Mulindwa DH, et al. Faecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban Kampala, Uganda: a community-based survey. *BMC Pediatr*. 2011;11:5–11.
57. Oord T, Hornung N. Fecal calprotectin in healthy children. *Scand J Clin Lab Invest*. 2014;74:254–8.
58. Zoppelli L, Güttel C, Bittrich HJ, André C, Wirth S, Jenke A. Fecal calprotectin concentrations in premature infants have a lower limit and show postnatal and gestational age dependence. *Neonatology*. 2012;102:68–74.
59. Josefsson S, Bunn S, Domellof M. Fecal calprotectin in very low birth weight infants. *J Pediatr Gastroenterol Nutr*. 2007;44:407–13.
60. Roseth A., Aadland E, Jahsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. *Digestion*. 1997;58:176–80.
61. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. *Am J Gastroenterol*. 2000;95:2831–7.
62. Komraus M, Wos H, Wiecek S, Kajor M, Grzybowska-Chlebowczyk U. Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease. *Mediators Inflamm*. 2012;2012:1–6.

63. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. *Inflamm Bowel Dis.* 2008;14:669–73.
64. Van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. *Inflamm Bowel Dis.* 2012;18:2018–25.
65. Diamanti A, Colistro F, Basso MS, Papadatou B, Francalanci P, Bracci F, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. *Inflamm Bowel Dis.* 2008;14:1229–35.
66. Joishy M, Davies I, Ahmed M, Wassel J, Davies K, Sayers A, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2009;48:48–54.
67. Mazurek S, Grimm H, Oehmke M, Weisse G, Teigelkamp S, Eigenbrodt E. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. *Anticancer Res.* 20:5151–4.
68. Czub E, Herzig KH, Szaflarska-Popławska A, Kiehne K, Socha P, Woś H, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. *Scand J Gastroenterol.* 2007;42:1147–50.
69. Czub E, Nowak JK, Moczko J, Lisowska A, Banaszekiewicz A, Banasiewicz T, et al. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in acute diarrhea in hospitalized children. *Sci Rep.* 2014;4:2–4.
70. Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. *Gut.* 2010;59:1207–12.
71. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. *J Leukoc Biol.* 2001;69:986–94.
72. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. *Inflamm Bowel Dis.* 2008;14:359–66.
73. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. *Bull World Health Organ.* 2003;81:197–204.
74. Naughton PJ, Clohessy PA, Grant G, Golden B. Faecal calprotectin : non-invasive marker of gastrointestinal inflammation in salmonella infected rats. *Biochem Soc Trans.* 1995;14:308S.
75. Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. *Aliment Pharmacol Ther.* 2002;16:675–81.

76. Lepe-Balsalobre E, Rubio-Sánchez R, Úbeda C, Úbeda Ontiveros JM. Diagnostic utility of fecal calprotectin in chronic diarrhea of bacterial etiology in pediatric patients. *Enfermedades Infecc y Microbiol Clin*. 2021;39:307–8.
77. Shastri YM, Bergis D, Povse N, Schäfer V, Shastri S, Weindel M, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. *Am J Med*. 2008;121:1099–106.
78. Duman M, Gencpinar P, Biçmen M, Arslan N, Özden Ö, Üzümlü Ö, et al. Fecal calprotectin: can be used to distinguish between bacterial and viral gastroenteritis in children? *Am J Emerg Med*. 2015;33:1436–9.
79. Goold E, Pearson L, Johnson LM. Can fecal calprotectin serve as a screen for necrotizing enterocolitis in infants? *Clin Biochem*. 2020;84:51–4.
80. Yuniati T. Peningkatan berat badan bayi baru lahir dengan seksio sesarea yang diberikan kombinasi ASI dengan susu formula mengandung probiotik dan nonprobiotik. *Sari Pediatri*. 2012;14:251–5.
81. Garg M, Leach ST, Coffey MJ, Katz T, Strachan R, Pang T, et al. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. *J Cyst Fibros*. 2017;16:631–6.
82. Oncel MY, Sari FN, Arayici S, Guzoglu N, Erdeve O, Uras N, et al. *Lactobacillus reuteri* for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. *Arch Dis Child - Fetal Neonatal*. 2014;99:F110-5.
83. Kolodziej M, Szajewska H. *Lactobacillus reuteri* DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: protocol of a randomised controlled trial. *BMJ Open*. 2017;7:1–5.
84. Melese B, Paulos W, Astawesegn FH, Gelgelu TB. Prevalence of diarrheal diseases and associated factors among under-five children in Dale District, Sidama zone, Southern Ethiopia: a cross-sectional study. *BMC Public Health*. 2019;19:1–10.
85. Tareke AA, Enyew EB, Takele BA. Pooled prevalence and associated factors of diarrhea among under-five years children in East Africa: a multilevel logistic regression analysis. *PLoS One*. 2022;17:1–16.
86. Shine S, Muhamud S, Adanew S, Demelash A, Abate M. Prevalence and associated factors of diarrhea among under-five children in Debre Berhan town, Ethiopia 2018: a cross sectional study. *BMC Infect Dis*. 2020;20:1–6.
87. Yusuf S, Haris S, Kadim M. Gambaran derajat dehidrasi dan gangguan fungsi ginjal pada diare akut. *Sari Pediatri*. 2016;13:221–5.
88. Fathia H, Tejasari M, Trusda SAD. Hubungan tingkat pendidikan dan pengetahuan ibu tentang diare dengan frekuensi kejadian diare balita di wilayah kerja Puskesmas Tamansari Bandung Oktober 2013–Maret 2014. *Global Medical & Health Communication (GMHC)*. 2015:13–8.
89. Budiyo B, Raharjo M, Aini N. Hubungan kualitas air minum dengan kejadian

diare pada balita di wilayah kerja puskesmas Banyuasin Kecamatan Loano Kabupaten Purworejo (the relationship between the quality of drinking water and the occurrence of diarrhea in children under five years in. *J Kesehat Masy.* 2016;4:309–406.

90. Rahmi D, Gayatri P. Laporan kasus berbasis bukti manfaat pemberian probiotik pada diare akut. *Sari Pediatr.* 2015;76–80.

